News

Home/News
News 2017-06-21T13:15:59+00:00
September 11, 2017
Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today provided an update on entrectinib—an orally bioavailable, CNS-active tyrosine ...
September 11, 2017
HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents and services for molecular profiling applications, today ...
September 11, 2017
CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis
NEWARK, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
September 11, 2017
STRATA Skin Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
HORSHAM, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
September 11, 2017
Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced that it has been issued patents covering its coagulation ...
September 11, 2017
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
ROCKVILLE, Md., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
September 11, 2017
Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
September 8, 2017
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
STRASBOURG, France -- (BUSINESS WIRE) -- Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that the results of ...
September 8, 2017
Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that new data on RXDX-105 – a VEGFR-sparing, ...
September 8, 2017
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive ...
September 8, 2017
BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference
ALAMEDA, Calif.-- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that ...
September 8, 2017
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy in Preclinical Models of Duchenne Muscular Dystrophy
PARIS, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, ...
September 7, 2017
OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio
NANTES, France-- (BUSINESS WIRE) -- Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated half-year financial results as of June 30, ...
September 7, 2017
ABIVAX and Evotec Enter Into Strategic Collaboration to Develop Novel Antiviral Agents
Hamburg, Germany and Paris, France, 7th September 2017 at 7:30am (CEST) - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and ABIVAX (Euronext Paris: FR0012333284 ...
September 7, 2017
Zealand and Orbit Discovery enter into research collaboration
Zealand Pharma A/S ("Zealand") and Orbit Discovery Ltd ("Orbit") announce that they have entered into a multi-target research collaboration to identify novel peptide therapeutics using ...
September 7, 2017
BioLife Solutions to Present at September Investment Conferences
BOTHELL, Wash., Sept. 7, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and ...
September 7, 2017
Kamada to Present Corporate Overview at Two Investor Conferences in September
REHOVOT, Israel, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, ...
September 7, 2017
TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma
SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
September 7, 2017
BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
RALEIGH, N.C., Sept. 7, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) presented three posters including results from an analysis of data which evaluated the ...
September 7, 2017
Rockwell Medical Appoints John G. Cooper to Board of Directors
WIXOM, Mich., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...
Page 24 of 48